Cytochrome P-450 polymorphisms and response to clopidogrel

New England Journal of Medicine

Volumn 360, Issue 21, 2009, Pages 2250-2251

  Miao, Jianting ^a   Liu, Rui ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ALLELE; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; GENETICS; HEART MUSCLE ISCHEMIA; HUMAN; NOTE;

ARYL HYDROCARBON HYDROXYLASES; HETEROZYGOTE; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 66149145864     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375
2. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896
3. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008;196:341-348
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004;15:427-433 (Pubitemid 38901614)
5. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-1169